Prognosis
Pfizer Says Booster Lifts Antibodies for Omicron Variants
- Companies release early antibody data on modified vaccine
- Amid slow booster campaign, Americans await efficacy data
This article is for subscribers only.
Pfizer Inc. and its German vaccine partner said their booster tailored to the latest omicron variants raised more antibodies against the dominant strains of Covid-19 when compared with the original shot designed to fight the form of the virus.
Blood from 80 volunteers collected seven days after the booster shot showed an increase in neutralizing antibodies against the BA.4 and BA.5 subvariants in a study, Pfizer and BioNTech SE said in a statement Thursday.